Developer: Eli Lilly and Company | Administration in Trials: Once-weekly subcutaneous injection First successful Phase 3 trial (TRIUMPH-4, topline Dec 2025): Up to 28.7% average body weight loss at 68 weeks (highest dose) in adults with obesity/overweight and knee osteoarthritis
Receptors are known to exhibit broad activity, which researchers have used to probe how these systems function in the body under laboratory conditions
However, studies indicate that consuming more foods high in vitamin C, such as grapefruit, may help with hyperpigmentation, discolouration, and other signs of ageing
Unlike many peptides that require injection to avoid degradation in the digestive system, DSIP demonstrates unusual stability
The short GHK-Cu half life leaves zero room for error
Circulation Changes (Why Hands & Feet Feel Colder) Peripheral circulation can slow during early weight loss or metabolic adaptation, reducing blood flow to hands and feet